发明名称 Antibodies Against TL1a and Uses Thereof
摘要 The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.
申请公布号 US2016333104(A1) 申请公布日期 2016.11.17
申请号 US201615206493 申请日期 2016.07.11
申请人 Teva Pharmaceuticals Australia Pty Ltd 发明人 Poulton Lynn Dorothy;Clarke Adam;Pow Andrew James;Tamvakis Debra;Kopsidas George;Doyle Anthony Gerard;Jennings Philip Anthony;Pollard Matthew
分类号 C07K16/28 主分类号 C07K16/28
代理机构 代理人
主权项 1. A recombinant antibody that specifically binds to TL1a, comprising a variable heavy chain (VH) and a variable light chain (VL), wherein the VL comprises the following complementary determining regions (CDRs): (i) a CDR1 comprising the sequence RASQSITNNLA comprising four or fewer amino acid substitutions; (ii) a CDR2 comprising the sequence DASTRAT comprising one or no amino acid substitution; and (iii) a CDR3 comprising the sequence QQYNNWPLT comprising three or fewer amino acid substitutions.
地址 Macquarie Park AU